Mittelschmerz is the mid-cycle lower abdominal pain some people experience at the time of ovulation. It happens when the ovarian follicle releases the egg and a small amount of fluid or blood irritates the peritoneal surfaces, producing a brief cramp-like sensation. The pain is usually on one side, aligning with which ovary is releasing the egg, and it tends to occur about halfway through the cycle, lasting from minutes to a day or two. This pain is different from menstrual cramps, which occur during menstruation, and it isn’t specifically tied to menopause or pregnancy. Many people don’t notice any symptoms, while others may have mild to moderate discomfort and sometimes light spotting or bloating. If the pain is severe, persistent, or comes with fever, vomiting, or heavy bleeding, seek medical evaluation to rule out other conditions.

A clear pattern for primary amenorrhea is that the body’s outflow pathway or its reproductive structures fail to develop or are obstructed, so menstrual blood cannot be produced or expelled. When congenital abnormalities of the reproductive system are present, especially where the uterus or upper vagina are missing (as in Müllerian agenesis) or where there is an outflow obstruction (like an imperforate hymen or a transverse vaginal septum), menses never occur despite normal early puberty. This explains why primary amenorrhea is often due to structural issues detected from birth or early adolescence. Endometriosis, by contrast, usually causes painful periods or infertility after menarche and is not a typical cause of primary amenorrhea. Weight loss can interfere with puberty by suppressing the hormonal axis, but it’s a less common cause of primary amenorrhea compared with congenital tract abnormalities. Pregnancy would result in no menses during pregnancy, but it is not a cause SAMPLEof primary amenorrhea in someone who has not yet had menarche.

SERMs act as estrogen receptor modulators, showing estrogen-like effects in some tissues and anti-estrogen effects in others. This mixed action leads to key safety concerns: they can increase the risk of forming blood clots, which can cause deep vein thrombosis, pulmonary embolism, or even stroke. In tissues where they act like estrogen, such as the uterine lining with drugs like tamoxifen, they can stimulate the endometrium and raise the risk of endometrial hyperplasia and cancer. Because of these clinically important effects, the combination of clotting risks, potential stroke, and uterine cancer risk best captures the main safety issues associated with SERMs. Hair loss and dry skin aren’t the primary risks, there isn’t an overall assumption of no side effects, and improved muscle strength isn’t a known major SERM risk or benefit.

Forteo (teriparatide) is an anabolic therapy for osteoporosis. It works by stimulating osteoblast activity to form new bone, unlike drugs that merely slow bone loss. It’s given as a daily subcutaneous injection, and treatment is limited to about two years due to safety concerns, including a potential risk of osteosarcoma seen in animal studies and limited human data. So the correct concept is an injection that promotes bone production, with a finite treatment duration. It is not a calcium supplement, a pain-relief NSAID, or an antibiotic, which is why those options don’t fit.